Stable Demand & Sustained Policy Focus,Chinese Medicine ETF(560080) Rises 1.32% Intraday

NewTimeSpace News: As of 13:45 on January 26, 2026, the CSI Chinese Medicine Index (930641) rose strongly by 1.06%. Its constituent stocks performed actively, with Yiling Pharmaceutical surging 8.54%, Zhongsheng Pharmaceutical climbing 7.62%, Tailong Pharmaceutical advancing 4.08%, and other stocks including Jiangzhong Pharmaceutical and Hongri Pharmaceutical following the upward trend. The Chinese Medicine ETF (560080) gained 1.32%, closing at RMB1.08 intraday. Looking back, as of January 23, 2026, the ETF had accumulated a 0.57% increase in the past week. (The stocks listed above are only index constituents and do not constitute specific investment recommendations.)

In terms of liquidity, the ETF achieved an intraday turnover rate of 4.98% with a trading volume of RMB122 million. Over a longer horizon, as of January 23, its average daily trading volume in the past year hit RMB72.0766 million, ranking first among comparable funds.

Regarding scale, the ETF’s latest size reached RMB2.433 billion, placing it in the top 25% of comparable funds. (Data source: Wind)

In terms of shares, the ETF added 573 million shares in the past six months, achieving significant growth, with the new share volume ranking in the top 50% of comparable funds. (Data source: Wind)

Data shows that leveraged funds have continued to increase their positions. The ETF’s latest margin purchase amount stood at RMB6.4162 million, with the latest margin balance reaching RMB67.4250 million. (Data source: Wind)

As of January 23, the ETF’s net value had risen by 2.84% in the past year. In terms of profitability, as of January 23, 2026, since its establishment, the ETF has recorded a maximum monthly return of 16.46%, the longest consecutive monthly gain period of 5 months with a cumulative increase of 20.20%, and an average return of 5.45% in rising months. Its annualized return exceeding the benchmark in the past two years was 2.40%, ranking in the top 50% of comparable funds.

In terms of drawdown, the ETF’s maximum drawdown since the start of 2026 was 1.37%, with a relative benchmark drawdown of 0.02%, indicating lower drawdown risk among comparable funds.

Regarding fees, the ETF’s management fee rate is 0.50% and the custodian fee rate is 0.10%, the lowest among comparable funds.

In terms of tracking accuracy, the ETF’s tracking error in the past month was 0.006% as of January 23, 2026, the highest among comparable funds.

From a valuation perspective, the CSI Chinese Medicine Index tracked by the ETF has a latest trailing twelve-month price-to-earnings (PE-TTM) ratio of only 24.41 times, at the 14.34th percentile of the past five years. This means the valuation is lower than 85.66% of the time over the past five years, standing at a historical low.

The Chinese Medicine ETF closely tracks the CSI Chinese Medicine Index, which selects listed company securities engaged in Chinese medicine production and sales as samples to reflect the overall performance of Chinese medicine concept listed companies.

Data shows that as of December 31, 2025, the top 10 constituent stocks by weight of the CSI Chinese Medicine Index (930641) were Yunnan Baiyao, Pien Tze Huang, Dong-E Ejiao, Tongrentang, China Resources Sanjiu Medical & Pharmaceutical, Jilin Aodong, Baiyunshan, Yiling Pharmaceutical, Daren Tang, and Zhongsheng Pharmaceutical. The combined weight of these top 10 stocks accounted for 56.04%. (The stocks listed above are only index constituents and do not constitute specific investment recommendations.)

China Lianhe Credit Rating Co., Ltd. stated that against the backdrop of population aging, the demand for China’s Chinese medicine industry remains stable. Meanwhile, national policies continue to focus on the innovation and high-quality development of traditional Chinese medicine. Progressive advancement of centralized procurement of Chinese medicines has not only achieved significant price reductions and expanded coverage but also accelerated industry restructuring, promoting the concentration of resources in leading enterprises with full industrial chain advantages and large-scale capabilities, and forcing the entire industry to transform and upgrade towards standardization and intensification.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.